Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine for postoperative depression and Homer1a expression in breast cancer surgery patients
ChiCTR2400082215Phase 4Not yet recruiting
- Sponsor
- General Hospital of Western Theater Command of PLA
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in major depressive disorder (MDD), anxiety disorder and postoperative pain (2 arms), sponsored by General Hospital of Western Theater Command of PLA. Primary endpoints: Hospital Anxiety and Depression Scale score and Homer1a protein. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)anxiety disorderpostoperative pain
Beyond the preview
Go deeper on ChiCTR2400082215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082215.